First Manhattan
DICE

First Manhattan’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

First Manhattan’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-155,904
Closed -$2.42M – 1701
2022
Q2 		$2.42M Sell
155,904
-24,218
-13% -$417K 0.01% 309
2022
Q1 		$3.44M Buy
+180,122
New +$3.21M 0.01% 292

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

First Manhattan's DICE Position: Q3 2022 in Review

First Manhattan sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2022, closing a stake of 155,904 shares — an estimated $2.42M sold.

First Manhattan first reported a position in DICE in Q1 2022 and held it in 2 quarters. The position peaked at $3.44M in Q1 2022. 79 funds tracked by Wall St. Rank hold DICE as of Q3 2022.

  • First Manhattan reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • First Manhattan sold 155,904 DICE Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.42M.
  • First Manhattan first reported a position in DICE Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • First Manhattan's DICE Therapeutics, Inc. Common Stock position peaked at $3.44M in Q1 2022.
  • 79 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2022.

Based on First Manhattan's 13F filing for Q3 2022, filed 14 Nov 2022.